Everolimus denied for missing prior authorization by Kaiser Permanente?

Kaiser Permanente's specific coverage criteria for everolimus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Kaiser Requires Prior Authorization for Everolimus — and How to Navigate It

Everolimus is a high-cost specialty drug used across oncology, tuberous sclerosis complex, and transplant medicine. Kaiser requires prior authorization (PA) for it to ensure the requested use meets clinical coverage criteria before the plan agrees to pay. A prior-auth-required denial — whether a flat denial of an initial PA request or a denial because a PA was never submitted — is one of the most straightforward denial types to address, because the path is clearly defined: gather the right documentation, map it to Kaiser's criteria, and submit a well-organized PA or appeal.

## The Federal Appeal Framework

If a prior authorization request was submitted and denied, you have full appeal rights under ACA §2719: internal appeal followed by independent external review (IRO) within four months of final internal denial. For urgent clinical situations, request expedited review — the plan must respond within 72 hours.

For self-funded employer plans, ERISA §503 governs: you are entitled to the specific clinical criteria applied in the denial, a full-and-fair internal review, and federal-court access after exhausting plan remedies.

If the drug was dispensed before a PA was obtained and Kaiser is denying retroactive coverage, note that most state insurance codes and ACA rules limit a plan's ability to deny retroactively when the patient had a good-faith belief coverage existed — check with your state insurance commissioner.

## What Kaiser Typically Requires for Everolimus PA

Kaiser's PA requirements are detailed in its published clinical policy. Generally, the criteria track the FDA-approved prescribing label, including confirmed diagnosis, relevant disease stage or biomarker status, treatment history, and prescribing specialty. Obtain Kaiser's current clinical policy document and confirm every criterion.

## Documentation to Gather

• Confirmed diagnosis and staging: Pathology report, imaging, relevant biomarker or genetic testing, and treating physician's diagnosis notes.
• Prior treatment history: Dated records of all therapies used before everolimus, showing duration and outcomes.
• Prescribing specialist's PA letter: A letter that addresses each Kaiser PA criterion individually, citing specific chart findings.
• FDA prescribing label: The current label showing the approved indication for this patient's condition.
• Applicable specialty guideline: Reference (without statistics) to the relevant NCCN or specialty society guideline recommending this agent.

## Criteria-Mapping Structure

| Kaiser PA Criterion for Everolimus | Chart Evidence Meeting It | |---|---| | [Copy each criterion from Kaiser's clinical policy] | [Specific chart finding, date, and document] |

## Practical Next Steps

1. Request Kaiser's published clinical policy for everolimus — you are entitled to the criteria applied to your case. 2. Compare the original PA submission against each criterion to identify any gaps. 3. Have the treating specialist write a letter explicitly addressing every criterion with chart citations. 4. Resubmit the PA with the criteria-mapping table and supporting records. 5. If the resubmission is denied, file for internal appeal and then independent external review promptly. 6. For urgent cases, request expedited PA review at the time of resubmission — Kaiser is required to process urgent requests on a compressed timeline.